Zoetis Inc. (NYSE:ZTS) Shares Sold by Brookstone Capital Management

Brookstone Capital Management lowered its position in shares of Zoetis Inc. (NYSE:ZTSFree Report) by 63.3% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,781 shares of the company’s stock after selling 8,249 shares during the quarter. Brookstone Capital Management’s holdings in Zoetis were worth $944,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. State Street Corp raised its stake in Zoetis by 1.1% during the second quarter. State Street Corp now owns 19,630,557 shares of the company’s stock valued at $3,380,578,000 after buying an additional 213,907 shares in the last quarter. Wellington Management Group LLP raised its stake in Zoetis by 2.5% during the third quarter. Wellington Management Group LLP now owns 12,344,692 shares of the company’s stock valued at $2,147,730,000 after buying an additional 297,044 shares in the last quarter. Morgan Stanley raised its stake in Zoetis by 34.6% during the fourth quarter. Morgan Stanley now owns 10,872,704 shares of the company’s stock valued at $1,593,395,000 after buying an additional 2,796,694 shares in the last quarter. Geode Capital Management LLC raised its stake in Zoetis by 0.3% during the first quarter. Geode Capital Management LLC now owns 9,739,370 shares of the company’s stock valued at $1,617,464,000 after buying an additional 27,097 shares in the last quarter. Finally, Northern Trust Corp raised its stake in Zoetis by 3.3% during the third quarter. Northern Trust Corp now owns 6,143,258 shares of the company’s stock valued at $1,068,804,000 after buying an additional 196,771 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

ZTS has been the subject of several recent research reports. Stifel Nicolaus upped their target price on Zoetis from $195.00 to $215.00 and gave the company a “buy” rating in a report on Friday, January 12th. Barclays upped their target price on Zoetis from $255.00 to $260.00 and gave the company an “overweight” rating in a report on Wednesday, February 14th. The Goldman Sachs Group upped their target price on Zoetis from $190.00 to $226.00 and gave the company a “buy” rating in a report on Wednesday, January 17th. Jefferies Financial Group reaffirmed a “buy” rating and set a $230.00 target price on shares of Zoetis in a report on Tuesday, December 19th. Finally, StockNews.com lowered Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 20th. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $224.33.

Check Out Our Latest Report on Zoetis

Insider Activity

In other news, EVP Roxanne Lagano sold 363 shares of the stock in a transaction on Monday, February 12th. The stock was sold at an average price of $197.74, for a total value of $71,779.62. Following the completion of the sale, the executive vice president now owns 20,417 shares in the company, valued at $4,037,257.58. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In the last 90 days, insiders sold 2,209 shares of company stock worth $408,453. Insiders own 0.15% of the company’s stock.

Zoetis Stock Performance

Shares of NYSE ZTS opened at $168.90 on Monday. The stock has a fifty day moving average price of $187.53 and a two-hundred day moving average price of $182.62. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.00 and a current ratio of 3.36. The firm has a market cap of $77.33 billion, a P/E ratio of 33.31, a PEG ratio of 2.58 and a beta of 0.87. Zoetis Inc. has a 1 year low of $151.03 and a 1 year high of $201.92.

Zoetis (NYSE:ZTSGet Free Report) last issued its quarterly earnings results on Tuesday, February 13th. The company reported $1.24 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.32 by ($0.08). Zoetis had a net margin of 27.43% and a return on equity of 51.25%. The firm had revenue of $2.21 billion for the quarter, compared to the consensus estimate of $2.19 billion. During the same period in the previous year, the business posted $1.15 earnings per share. The business’s revenue for the quarter was up 8.5% compared to the same quarter last year. Research analysts forecast that Zoetis Inc. will post 5.8 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Friday, April 19th will be given a dividend of $0.432 per share. The ex-dividend date of this dividend is Thursday, April 18th. This represents a $1.73 dividend on an annualized basis and a dividend yield of 1.02%. Zoetis’s dividend payout ratio (DPR) is presently 34.12%.

About Zoetis

(Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Further Reading

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTSFree Report).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.